Active, not recruitingPhase 3NCT05863351
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
Studying Chromophobe renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Principal Investigator
- Raquibul HannanECOG-ACRIN Cancer Research Group
- Intervention
- Computed Tomography(procedure)
- Enrollment
- 472 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2037
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- UCHealth University of Colorado Hospital, Aurora, Colorado, United States
- Poudre Valley Hospital, Fort Collins, Colorado, United States
- Cancer Care and Hematology-Fort Collins, Fort Collins, Colorado, United States
- UCHealth Greeley Hospital, Greeley, Colorado, United States
- UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States
- Medical Center of the Rockies, Loveland, Colorado, United States
- Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- OSF Saint Joseph Medical Center, Bloomington, Illinois, United States
- Illinois CancerCare-Bloomington, Bloomington, Illinois, United States
- Illinois CancerCare-Canton, Canton, Illinois, United States
- Illinois CancerCare-Carthage, Carthage, Illinois, United States
- Centralia Oncology Clinic, Centralia, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05863351 on ClinicalTrials.govOther trials for Chromophobe renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07485114Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 InhibitorsDaniel Keizman
- RECRUITINGPHASE3NCT07227402A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT07233252Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic CancerTianjin Medical University Second Hospital
- RECRUITINGNANCT07171190Targeted Abdominal CT in Conjunction With Lung Cancer ScreeningUniversity of Cambridge
- RECRUITINGPHASE2NCT07050771Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer SurgeryThe Methodist Hospital Research Institute
- RECRUITINGPHASE2NCT06642220Ablative Radioembolization of Renal Cell Carcinoma TrialDerek W. Cool
- RECRUITINGNCT06889974Timing of Renal Replacement Therapy Initiation in Tumor Lysis SyndromeUniversity Hospital, Bordeaux
- ENROLLING BY INVITATIONNCT07307157Head-to-Head Evaluation of the Cancer Ontology Supervised Multimodal Orchestration (COSMO) AI System Versus Pathologist-Only ReviewHarvard Medical School (HMS and HSDM)